JRK

Across TCGA pan-cancer cohorts, JRK RNA is linked to patient survival in 28 of 34 cancer types, making it the most broadly survival-associated JRK data layer compared with 6 for mutation status and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher JRK RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated JRK expression acts as an unfavorable survival marker, although some lineages such as HNSC and THYM show a favorable association.

ACC, LIHC, and HNSC are the cancer types where JRK RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.397	0.758	<.001	94	view →
LIHC	DFS	Quartile	All	0.398	0.630	<.001	76	view →
HNSC	DFS	Median	IV	0.393	0.241	.002	57	view →
UVM	DFS	Quartile	All	0.273	0.917	<.001	53	view →
COAD	DFS	Median	IV	0.232	0.719	<.001	41	view →
CESC	DFS	Median	All	0.774	0.871	.002	28	view →
MESO	DFS	Quartile	All	0.337	0.937	.006	27	view →
THCA	DFS	Median	IV	0.457	0.865	.002	23	view →
LUSC	DFS	Tertile	III,IV	0.348	0.855	.011	22	view →
THYM	DFS	Quartile	II,III,IV	1.000	0.562	.004	20	view →
BRCA	OS	Tertile	II,III,IV	0.437	0.672	.001	18	view →
KIRC	DFS	Tertile	All	0.900	0.727	.001	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 28 lineages.

JRK–ACC (DFS)

Open the ACC breakdown →